(Health-NewsWire.Net, August 12, 2021 ) Primary Research:
Primary research was conducted after acquiring extensive knowledge about the global fertility test market scenario through secondary research. Primary interviews were conducted with market experts from both the demand-side (such as hospitals, fertility clinics, research universities, academic institutions, and government institutions, among others) and supply-side respondents (such as presidents, CEOs, vice presidents, directors, general managers, heads of business units, and senior managers) across five major geographies, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East, and Africa.
Approximately 30% of the primary interviews were conducted with stakeholders from the demand side, while those from the supply side accounted for the remaining 70%. Primary data for this report was collected through questionnaires, emails, and telephonic interviews.
The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B), white papers, annual reports, companies house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the fertility test market. A database of the key industry leaders was also prepared using secondary research.
Download PDF Brochure@
Expected Revenue Growth:
The fertility test market is projected to reach USD 680 Million by 2025 from USD 472 Million in 2020, at a CAGR of 7.5 % the forecast period. Growth in this market is primarily driven by by the increasing first-time pregnancy age in women, declining fertility rate among men and women, growing number of women suffering from disorders such as PCOS, emergence of advanced ovulation monitors, and the increased awareness of fertility testing in both developed as well as developing countries.
COVID-19 Impact on the global Fertility Test Market
The COVID-19 pandemic has emerged as a huge challenge for the global fertility market. In the initial stages of the pandemic, authorities recommended the suspension of all in-person fertility treatments. For instance, in March 2020, the American Society of Reproductive Medicine and the Canadian Fertility and Andrology Society announced their recommendations to instantly and for the foreseeable future suspend all in-person fertility treatments in the US and Canada due to COVID-19.
One in six reproductive-aged couples experiences infertility, and many turn to treatments such as IUI and IVF, which require several in-person appointments to complete. Around 3 million people seek infertility treatment in India every year, but only 0.5 million people undergo IVF/Intrauterine Insemination (IUI) procedure. As per data, of the 1,100 centers across India, an ~90% drop was observed in the number of people undergoing IVF cycles between April and June 2020.
The home care settings segment is expected to register the highest CAGR during the forecast period
Based on end-users, the fertility test market has been segmented based on end-user category—home care settings, hospitals and fertility clinics, and other end users. The large share and high growth of this segment can be attributed to the inclination of patients toward self-monitoring of healthcare conditions, easy access to fertility and ovulation monitors on e-commerce websites, availability of user-friendly and easy-to-handle devices, and the growing preference for the confidentiality of test results.
North America dominated the global fertilty test market in 2020
North America, comprising the US and Canada, accounted for the largest share of the fertility test market in 2020. The large share of this region can primarily be attributed to factors such as high prevalence of infertility, increasing awareness about fertility testing among women, the rising age of first-time pregnancies in women, and the easy availability of ovulation and fertility monitors through e-commerce websites.
Swiss Precision Diagnostics (Switzerland), Church & Dwight (US), Prestige Brands Holdings (US), bioZhena (US), Fairhaven Health (US), Fertility Focus (UK), Geratherm Medical (Germany), Hilin Life Products (US), UEBE Medical (Germany), AdvaCare Pharma (US), AVA (Switzerland), Babystart (UK), Valley Electronics (Germany), Sensiia (UK), and Mira Care (US), among others are some of the major players operating in the global fertility test market.
Request Sample Pages@
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
Mr. Aashish Mehra